Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | MMP1 | P03956 | 1/20 | 0.63 |
| ▸ | MMP2 | P08253 | 1/20 | 0.63 |
| ▸ | MMP9 | P14780 | 1/20 | 0.63 |
| ▸ | MMP8 | P22894 | 1/20 | 0.63 |
| ▸ | MMP13 | P45452 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27917300 | 0.87 | CA1 (0.59) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL27870758 | 0.87 | CA1 (0.59) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL9375398 | 0.87 | CA1 (0.59) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL31153073 | 0.86 | CA1 (0.58) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL14094466 | 0.84 | CA1 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL11064560 | 0.84 | CA1 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL23779412 | 0.83 | CA1 (0.55) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL12207830 | 0.83 | CA1 (0.59) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL23779409 | 0.83 | CA1 (0.55) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL11527174 | 0.83 | CA1 (0.59) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127800-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | SIGNET THERAPEUTICS INC. (CN) | 2025-04-24 | — | — | US | disclosed |
| EP-4450493-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | Signet Therapeutics Inc. (CN) | 2024-10-23 | — | — | EP | disclosed |
| CN-117043151-A | Pyrimidine or pyridine derivative and medical application thereof | 希格生科（深圳）有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023109751-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | 希格生科（深圳）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-108948019-B | Focal adhesion kinase inhibitors and uses thereof | 广东东阳光药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-9580439-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-02-28 | — | — | US | disclosed |
| CN-103588704-B | INHIBITORS OF FOCAL ADHESION KINASE | 斯克里普斯研究学院 | 2016-09-14 | — | — | CN | disclosed |
| CN-102093364-B | 2,4-diamido-6,7-dihydro-5H-pyrrolo [2,3] pyrimidine derivative as focal adhesion kinase/pyruvate kinase 2 (FAK/Pyk2) inhibitor | CENTAURUS BIOPHARMA CO LTD | 2015-01-28 | — | — | CN | disclosed |
| EP-2727909-A1 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2134689-B1 | INHIBITORS OF FOCAL ADHESION KINASE | SCRIPPS RESEARCH INST (US) | 2014-04-23 | — | — | EP | disclosed |
| CN-101146530-A | 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension | NOVARTIS AG (CH) | 2008-03-19 | — | — | CN | disclosed |
| EP-1863477-A1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Novartis AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| US-5783699-A | MAY BE CONJUGATED TO ANTIGENS, HAPTENS, ANTIBODIES IN IMMUNOASSAYS | ABBOTT LABORATORIES (US) | 1998-07-21 | — | — | US | disclosed |
| US-5669819-A | IMMUNOASSAY | ABBOTT LABORATORIES (US) | 1997-09-23 | — | — | US | disclosed |
| US-5565570-A | REACTING AMINE WITH SULFONYL HALIDE IN INERT SOLVENT IN PRESENCE OF BASE TO FORM METAL SALT OF SULFONAMIDE, ACYLATING WITH ACTIVATED PHENANTHRIDINE-6-CARBOXYLIC ACID TO FORM CHEMILUMINESCENT SALT | ABBOTT LABORATORIES (US) | 1996-10-15 | — | — | US | disclosed |
| US-5545739-A | E.G., 5-METHYL-6-(N-2-CARBOXYETHYL-N=(2-CARBOXYETHYL)-PHENANTHRIDIN IUMCARBOXAMIDE CHLORIDE; IMMUNOASSAYS; STABILITY; SENSITIVITY | ABBOTT LABORATORIES (US) | 1996-08-13 | — | — | US | disclosed |
| US-5543524-A | FORMING A SULFONAMIDE FROM AND AMINE AND A SULFONYL HALIDE AND AND ACYLATING WITH A CARBONYL HALIDE OF AN ACTIVATED ACRIDINE SALT | ABBOTT LABORATORIES (US) | 1996-08-06 | — | — | US | disclosed |
| US-5468646-A | Chemiluminescent acridinium salts | ABBOTT LABORATORIES (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0273115-B1 | Chemiluminescent acridinium and phenanthridinium salts | ABBOTT LAB (US) | 1994-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127800-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | PTK2, PDGFRB, PTK2B | CA1 4752/4885CA2 2548/4885MMP1 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.